Skip to content

Application of Decrement-Evoked Potential (DEEP) mapping during Atrial Fibrillation Ablation

An observational study of Decrement-Evoked Potential (DEEP) mapping during standard Atrial Fibrillation Ablation to establish feasibility and predictive power for Atrial Fibrillation Recurrence

Status
Not yet recruiting
Phases
Unknown
Study type
Observational
Source
ANZCTR
Registry ID
ACTRN12618001815257
Acronym
Atrial DEEP
Enrollment
75
Registered
2018-11-07
Start date
2018-11-13
Completion date
2019-04-10
Last updated
2018-11-12

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Brief summary

In the proposed study, the treating electrophysiologist will use a new and more focused method to help him/her in identifying the pathological potentials that are responsible for initiation and maintenance of AF. Despite many efforts globally, there has been a lack of ability to find and prove the best targets for ablation outside the pulmonary veins for AF, which is of particular interest in improving the success of ablation for persistent AF. There is recent evidence for the DEEP method in mapping for VT procedures. The proposed method is based on a mechanistic concept that regions that participate in the initiation of AF will demonstrate significant decremental properties prior to block and reentry, when stressed by a closely coupled premature beat. This method simply requires some additional pacing and mapping of the response to this during the routine post-ablation waiting period while patients are already undergoing AF ablation. In this study, mapping of DEEP will be performed to determine its feasibility in atrial tissue, and the presence of DEEP will be tested as a predictor of recurrence of AF during the follow-up period of 12 months. Areas of DEEP will also be compared in location and extent to abnormal voltage and complex signals seen on standard mapping (such as complex fractionated atrial electrograms and re-entrant areas). Fifteen participants will be recruited at each of 5 international centres for a total of 75 participants.

Interventions

The study procedure involves the addition of pacing manoeuvres to map additional potentials called Decrement Evoked Potentials (DEEP), during standard procedures for ablation of persistent AF in patients who are clinically referred for an AF ablation procedure. The feasibility of delivering this pacing and measuring responses in atrial tissue will be tested, the relationship of DEEP areas to areas of scar and other signal abnormalities on voltage and activation mapping established (DEEP has rece

The study procedure involves the addition of pacing manoeuvres to map additional potentials called Decrement Evoked Potentials (DEEP), during standard procedures for ablation of persistent AF in patients who are clinically referred for an AF ablation procedure. The feasibility of delivering this pacing and measuring responses in atrial tissue will be tested, the relationship of DEEP areas to areas of scar and other signal abnormalities on voltage and activation mapping established (DEEP has recently shown promise in guiding ventricular tachycardia ablation) and the ability of DEEP to predict which patients will have AF recurrence explored. Pacing will be delivered at the end of the procedure by the electrophysiologist, after pulmonary vein isolation ablation, and will be with a drive train (S1=500ms) and extra stimulus (S2) at atrial Effective Refractory Period + 20ms, from specific protocol-specified sites in the left atrium. These include the left atrial appendage, roof, inferior-posterior wall, superior-posterior wall, anterior wall, mitral isthmus, high septum, low septum and inferior left atrium. Pacing for DEEP mapping will occur during the standard post-ablation waiting time, and will be additional to the usual ablation procedure, but will result in minimal additional procedural time compared to standard AF ablation. All analysis of DEEP will be performed offline post-procedure. Follow-up duration will be 12 months.

Sponsors

John Hunter Hospital Cardiology Department
Lead SponsorHospital

Eligibility

Sex/Gender
All
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

Recurrent Atrial Fibrillation ablation, referred for catheter ablation.

Exclusion criteria

Unable to provide informed consent. Pregnant women.

Outcome results

None listed

Source: ANZCTR · Data processed: Feb 4, 2026